Your browser doesn't support javascript.
loading
The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration.
Bedlington, Nicole; Abifadel, Marianne; Beger, Birgit; Bourbon, Mafalda; Bueno, Héctor; Ceska, Richard; Cillíková, Kristýna; Cimická, Zdenka; Daccord, Magdalena; de Beaufort, Carine; Dharmayat, Kanika I; Ference, Brian A; Freiberger, Tomás; Geanta, Marius; Gidding, Samuel S; Groselj, Urh; Halle, Martin; Johnson, Neil; Novakovic, Tanja; Májek, Ondrej; Pallidis, Athanasios; Peretti, Noel; Pinto, Fausto J; Ray, Kausik Kosh; Rees, Bleddyn; Reeve, John; Reiner, Zeljko; Santos, Raul D; Schunkert, Heribert; Sikonja, Jaka; Sokolovic, Milka; Tokgözoglu, Lale; Vrablík, Michal; Wiegman, Albert; Gutiérrez-Ibarluzea, Iñaki.
Afiliação
  • Bedlington N; FH Europe, Star House, Rochester, UK.
  • Abifadel M; Laboratory of Biochemistry & Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie-Santé, Saint Joseph University of Beirut, Beirut, Lebanon.
  • Beger B; Laboratory for Vascular Translational Science, Paris Cité University, Paris, France.
  • Bourbon M; Sorbonne Paris Nord University, INSERM, Paris, France.
  • Bueno H; European Heart Network, European Alliance for Cardiovascular Health, Brussels, Belgium.
  • Ceska R; Unidade de I&D, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal.
  • Cillíková K; BioISI - Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal.
  • Cimická Z; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
  • Daccord M; Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • de Beaufort C; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Dharmayat KI; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain.
  • Ference BA; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
  • Freiberger T; 3rd Department of Medicine - Department of Endocrinology & Metabolism of the 1st Faculty of Medicine, Charles University & General University Hospital, Prague, Czech Rep.
  • Geanta M; Diagnoza FH, Libán, Czech Rep.
  • Gidding SS; Diagnoza FH, Libán, Czech Rep.
  • Groselj U; FH Europe, Star House, Rochester, UK.
  • Halle M; Diabetes & Endocrine Care Clinique Pediatrique/CHL, Luxembourg, Grand Duchy Luxembourg.
  • Johnson N; Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK.
  • Novakovic T; University Of Cambridge, Clinical School, Cambridge, UK.
  • Májek O; Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Rep.
  • Pallidis A; Medical Faculty, Masaryk University, Brno, Czech Rep.
  • Peretti N; FH Europe, Star House, Rochester, UK.
  • Pinto FJ; FH Europe, Star House, Rochester, UK.
  • Ray KK; Department of Endocrinology, Diabetes & Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
  • Rees B; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Reeve J; Department of Prevention & Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Reiner Z; Deutsches Zentrum für Herz-Kreislauf-Forschung, Munich Heart Alliance, Munich, Germany.
  • Santos RD; Global Heart Hub, Galway, Ireland.
  • Schunkert H; ZEM Solutions Ltd, Belgrade, Serbia.
  • Sikonja J; National Screening Centre, Institute of Health Information & Statistics of the Czech Republic, Prague, Czech Rep.
  • Sokolovic M; Institute of Biostatistics & Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Rep.
  • Tokgözoglu L; LDL Greece, Athens, Greece.
  • Vrablík M; Department of Pediatric Gastroenterology-Hepatology & Nutrition, Hospices Civil de Lyon HCL, Hôpital Femme Mere Enfant HFME, Bron, France.
  • Wiegman A; Univ-Lyon, CarMeN laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon-1, Oullins, Lyon, France.
  • Gutiérrez-Ibarluzea I; World Heart Federation, Geneva, Switzerland.
GMS Health Innov Technol ; 16: Doc04, 2022.
Article em En | MEDLINE | ID: mdl-36311985
Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article